JP2022504468A5 - - Google Patents

Info

Publication number
JP2022504468A5
JP2022504468A5 JP2021519139A JP2021519139A JP2022504468A5 JP 2022504468 A5 JP2022504468 A5 JP 2022504468A5 JP 2021519139 A JP2021519139 A JP 2021519139A JP 2021519139 A JP2021519139 A JP 2021519139A JP 2022504468 A5 JP2022504468 A5 JP 2022504468A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
peptide
chemotherapy
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504468A (ja
JP7542529B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/051129 external-priority patent/WO2020079692A1/en
Publication of JP2022504468A publication Critical patent/JP2022504468A/ja
Publication of JP2022504468A5 publication Critical patent/JP2022504468A5/ja
Priority to JP2024137500A priority Critical patent/JP7862486B2/ja
Application granted granted Critical
Publication of JP7542529B2 publication Critical patent/JP7542529B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519139A 2018-10-17 2019-10-17 転移性膵臓腺癌の処置 Active JP7542529B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024137500A JP7862486B2 (ja) 2018-10-17 2024-08-19 転移性膵臓腺癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746587P 2018-10-17 2018-10-17
US62/746,587 2018-10-17
PCT/IL2019/051129 WO2020079692A1 (en) 2018-10-17 2019-10-17 Treatment of metastatic pancreatic adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024137500A Division JP7862486B2 (ja) 2018-10-17 2024-08-19 転移性膵臓腺癌の処置

Publications (3)

Publication Number Publication Date
JP2022504468A JP2022504468A (ja) 2022-01-13
JP2022504468A5 true JP2022504468A5 (cg-RX-API-DMAC7.html) 2022-10-12
JP7542529B2 JP7542529B2 (ja) 2024-08-30

Family

ID=68426576

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519139A Active JP7542529B2 (ja) 2018-10-17 2019-10-17 転移性膵臓腺癌の処置
JP2024137500A Active JP7862486B2 (ja) 2018-10-17 2024-08-19 転移性膵臓腺癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024137500A Active JP7862486B2 (ja) 2018-10-17 2024-08-19 転移性膵臓腺癌の処置

Country Status (11)

Country Link
US (2) US12291570B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866812A1 (cg-RX-API-DMAC7.html)
JP (2) JP7542529B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210095139A (cg-RX-API-DMAC7.html)
CN (3) CN118356479A (cg-RX-API-DMAC7.html)
AU (2) AU2019360044B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007318A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115802A1 (cg-RX-API-DMAC7.html)
IL (2) IL308722B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021004291A (cg-RX-API-DMAC7.html)
WO (1) WO2020079692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2025032571A1 (en) * 2023-08-07 2025-02-13 Biolinerx Ltd. Unit dosage forms and methods comprising bl8040 for intravenous administration
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors
SE2430349A1 (en) * 2024-06-27 2025-12-28 Linda Bojmar Liver tissue-based methods for predicting cancer recurrence and tailoring treatment approaches

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
EP1323730B1 (en) 2000-09-05 2010-04-21 Biokine Therapeutics Ltd. Novel polypeptides and anti-hiv drugs containing the same
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
BRPI1014854A2 (pt) 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
EA201200486A1 (ru) 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
US20180179282A1 (en) * 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
MX2017016844A (es) * 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
EP3791876A1 (en) * 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148744A1 (en) 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911353A1 (en) 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2021009761A1 (en) 2019-07-18 2021-01-21 Biolinerx Ltd. Combination therapy for the treatment of cancer
US11599666B2 (en) 2020-05-27 2023-03-07 Sap Se Smart document migration and entity detection
US12268725B2 (en) 2020-12-30 2025-04-08 Biolinerx Ltd. Composition of BL-8040

Similar Documents

Publication Publication Date Title
FI3849534T3 (fi) Yhdistelmähoidot
RU2747124C2 (ru) Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
JP2018528185A5 (cg-RX-API-DMAC7.html)
JP2019516733A5 (cg-RX-API-DMAC7.html)
IL263110B (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
JP2021512149A5 (cg-RX-API-DMAC7.html)
RU2015100529A (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан
JP2018514510A5 (cg-RX-API-DMAC7.html)
JP2022509262A5 (cg-RX-API-DMAC7.html)
JP2020516646A5 (cg-RX-API-DMAC7.html)
IL320452A (en) Combination therapy for prostate cancer
CN109985237B (zh) 一种治疗结直肠癌的药物组合物及其应用
JP2024516363A5 (cg-RX-API-DMAC7.html)
RU2019114952A (ru) Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин
JP2006513184A5 (cg-RX-API-DMAC7.html)
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
JP2019534251A5 (cg-RX-API-DMAC7.html)
Fukuoka et al. Clinical studies of irinotecan alone and in combination with cisplatin
JP2016505050A5 (cg-RX-API-DMAC7.html)
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP2021517886A5 (cg-RX-API-DMAC7.html)